Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, ...

National Cancer Institute Director Anthony Letai, M.D., Ph.D., has attempted to fight back against the “misinformation” ...

McKesson let go of a minority share of its medical/surgical solutions division for $1.25 billion to Apollo Funds as part of ...

A little over a year after reabsorbing its anticoagulant abelacimab, Novartis has now terminated two phase 3 trials for the ...

AcuityMD has raised $80 million—with a company valuation now nearing $1 billion—to use its artificial intelligence (AI) ...

Kyverna Therapeutics has unveiled the full results from its registrational trial of miv-cel in stiff person syndrome (SPS), ...

Roche has shared details of fatalities in its phase 3 relapsing multiple sclerosis (RMS) trials, revealing that deaths from ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution ...

Replimune is saying goodbye to a further 161 employees across two Massachusetts sites as the company continues to reel from ...

A pair of Sage Therapeutics veterans has launched a neurology-focused startup armed with $106 million and a clinical-stage ...

Gene therapy biotech Ray Therapeutics has announced the closing of a $125 million series B financing to support the company’s ...

Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building ...